Business Context and Reporting Period
This Form 8-K Current Report was filed by Moderna, Inc. on April 18, 2021. The filing details a material event involving an amendment to a government contract regarding the advancement of the Moderna COVID-19 Vaccine (mRNA-1273).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for the period. Specific financial figures disclosed relate solely to the government contract:
- Contract Value Increase: The maximum award under the BARDA Contract increased by $236 million.
- New Maximum Award: Approximately $1.25 billion (up from approximately $1.0 billion).
- Remaining Funding (Pre-Amendment): As of March 31, 2021, remaining available funding net of revenue earned was $317 million.
Material Changes
On April 18, 2021, ModernaTX, Inc., a wholly-owned subsidiary, entered into an amendment with the Biomedical Advanced Research and Development Authority (BARDA). The amendment increases the total funding available for clinical studies, manufacturing scale-up, and pharmacovigilance efforts associated with the vaccine.
Outlook, Risks, and Contingencies
Management Commentary: The Company submits expense requests regularly to BARDA for review and reimbursement. All requests are subject to detailed review by BARDA prior to payment.
Risks and Contingencies: The contract includes standard government provisions, including the right for the government to terminate the contract at any time for its convenience. The full text of the Amendment will be filed as an exhibit to the Form 10-Q for the period ending June 30, 2021.
Investor Verification Checklist
- Verify the specific terms of the Amendment once filed as an exhibit to the Q2 2021 Form 10-Q.
- Monitor the Company's expense reimbursement requests and BARDA's approval process.
- Assess the risk of government contract termination for convenience.
- Review upcoming quarterly reports for the actual revenue recognition resulting from this increased funding cap.
